secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001628280-26-025365
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q1 adj. EPS $1.15, +6% YoY; acquires Exact Sciences; FY guidance $5.38-$5.58
--------------------------------------------------------------------------------

- Q1 GAAP diluted EPS $0.61; adjusted diluted EPS $1.15 (+6% YoY).
- Q1 sales $11.16B, reported +7.8%, comparable +3.7%.
- Completed Exact Sciences acquisition March 23; adds $0.20 dilution to FY EPS guidance.
- FY2026 guidance: comparable sales growth 6.5%-7.5%; adjusted EPS $5.38-$5.58.
- Medical Devices +8.5% comparable; Diabetes CGM +7.6% comparable; Nutrition -7.7% comparable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828026025365/0001628280-26-025365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828026025365/abt-20260416.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-025365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer